000950 重药控股
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.4693.3832.5115.7139.303
总资产报酬率 ROA (%)0.2530.5820.4351.0351.782
投入资产回报率 ROIC (%)0.4160.9660.7381.7102.795

边际利润分析
销售毛利率 (%)6.8547.2057.4347.9938.581
营业利润率 (%)1.1970.8280.6981.2312.116
息税前利润/营业总收入 (%)1.9911.7102.0382.8933.784
净利润/营业总收入 (%)0.9710.6320.4990.9321.715

收益指标分析
经营活动净收益/利润总额(%)154.129169.722129.526108.17482.894
价值变动净收益/利润总额(%)40.28261.38473.42232.87820.079
营业外收支净额/利润总额(%)0.297-1.639-0.9210.1502.545

偿债能力分析
流动比率 (X)1.1961.2181.3031.2721.198
速动比率 (X)0.9961.0041.0771.0721.004
资产负债率 (%)75.65775.00875.29175.63877.776
带息债务/全部投入资本 (%)71.01969.72969.68966.94969.010
股东权益/带息债务 (%)39.01841.54440.36146.04442.106
股东权益/负债合计 (%)22.49323.21922.57923.35823.946
利息保障倍数 (X)2.5191.9101.5141.7422.346

营运能力分析
应收账款周转天数 (天)167.446150.646145.517139.277144.535
存货周转天数 (天)47.16947.09744.84841.08940.388